TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22683195

Group type: EXPERIMENTAL
Intervention: Iomeprol 400 mgI/mL (100 mL)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Iodixanol 320 mgI/mL (125 mL)
Number of subjects: 110
Study: 20492615

Group type: EXPERIMENTAL
Intervention: PRT-PLTs
Number of subjects: 118

Group type: COMPARATOR
Intervention: Reference group
Number of subjects: 118
Study: 18803866

Group type: EXPERIMENTAL
Intervention: B-vitamin supplementation (folic acid 2 mg, vitamin B6 25 mg, vitamin B12 0.5 mg)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: B-vitamin supplementation
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: B-vitamin supplementation (meta-analysis)
Number of subjects: 162
Study: 15695545

Group type: EXPERIMENTAL
Intervention: Combined ilioinguinal blockade and local infiltration anaesthesia
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo (local infiltration anaesthesia only)
Number of subjects: 160
Study: 11886733

Group type: EXPERIMENTAL
Intervention: Initial training on a manikin with computer-based voice advisory feedback
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Overtrained group (10 similar 3 min training sessions during 1 week)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (no additional training)
Number of subjects: 35
Study: 10423050

Group type: EXPERIMENTAL
Intervention: Low-energy helium-neon laser (LEL)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo light treatment
Number of subjects: 30
Study: 7594252

Group type: EXPERIMENTAL
Intervention: Nursing intervention to alter the feeding environment
Number of subjects: 0
Study: 3236940

Group type: EXPERIMENTAL
Intervention: 75 mg cinnarizine
Number of subjects: 10

Group type: COMPARATOR
Intervention: 75 mg diphenhydramine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 28637262

Group type: EXPERIMENTAL
Intervention: Intensive anti‐smoking counseling
Number of subjects: 23

Group type: COMPARATOR
Intervention: Counseling and nicotine replacement therapy
Number of subjects: 23
Study: 28209740

Group type: EXPERIMENTAL
Intervention: Head-down tilt (HDT) with ambient air
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Head-down tilt (HDT) with 0.5% CO2
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Exposure to 3% CO2 after HDT (ambient air)
Number of subjects: 6
Study: 25613907

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control
Number of subjects: 92
Study: 23373742

Group type: EXPERIMENTAL
Intervention: Classroom presentation by older-peer educators
Number of subjects: 1120

Group type: EXPERIMENTAL
Intervention: Classroom presentation by health professionals
Number of subjects: 1120

Group type: EXPERIMENTAL
Intervention: Exploration of a museum exhibition
Number of subjects: 1120

Group type: EXPERIMENTAL
Intervention: Exploration of an internet-based virtual museum
Number of subjects: 1120

Group type: COMPARATOR
Intervention: No intervention (comparison group)
Number of subjects: 1120
Study: 21062997

Group type: COMPARATOR
Intervention: MPG 0/1 group
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: MPG 2/3 group
Number of subjects: 139
Study: 18294324

Group type: EXPERIMENTAL
Intervention: Published RaCTs
Number of subjects: 116

Group type: COMPARATOR
Intervention: Unpublished RaCTs
Number of subjects: 116
Study: 20512273

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl (100 microg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Intravenous fentanyl (100 microg)
Number of subjects: 29
Study: 16281143

Group type: EXPERIMENTAL
Intervention: XCF‐Q160AW prototype colonoscope
Number of subjects: 280

Group type: COMPARATOR
Intervention: Standard colonoscope (Olympus 140 series)
Number of subjects: 280
Study: 12182982

Group type: EXPERIMENTAL
Intervention: Continuous Accelerated Hyperfractionated (CAHF) radiotherapy at 1.5 Gy/fraction b.i.d. (6‐h interval), 5 d/wk, total dose 66 Gy in 44 fractions during 4.4 weeks
Number of subjects: 101

Group type: COMPARATOR
Intervention: Late-course Accelerated Hyperfractionated (LCAF) radiotherapy, conventional fractionation at 1.8 Gy/fraction to 41.4 Gy in 23 fractions during 4.6 weeks, followed by accelerated fractionation RT at 1.5 Gy/fraction
Number of subjects: 101
Study: 9630269

Group type: EXPERIMENTAL
Intervention: 3-D phase contrast (PC) magnetic resonance angiography (MRA)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Digital subtraction angiography (DSA)
Number of subjects: 22
Study: 7943791

Group type: EXPERIMENTAL
Intervention: Fast injection rate (0.5 mL/s) of 0.3% hypobaric bupivacaine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Slow injection rate (0.02 mL/s) of 0.3% hypobaric bupivacaine
Number of subjects: 18
Study: 3129589

Group type: EXPERIMENTAL
Intervention: Weighted nasoenteric feeding tubes
Number of subjects: 116

Group type: COMPARATOR
Intervention: Unweighted nasoenteric feeding tubes
Number of subjects: 116
Study: 11590524

Group type: EXPERIMENTAL
Intervention: Nelfinavir-containing therapy (PI treatment)
Number of subjects: 120

Group type: COMPARATOR
Intervention: RTI therapy alone
Number of subjects: 120
Study: 31517324

Group type: EXPERIMENTAL
Intervention: Diet plus nutritional orientation (DIET group, n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Only nutritional orientation (Control group, n=20)
Number of subjects: 40
Study: 30342539

Group type: EXPERIMENTAL
Intervention: Movement through Active Personalised engagement programme (intervention group)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 338
Study: 26820612

Group type: EXPERIMENTAL
Intervention: Pre-Visit Prioritization intervention
Number of subjects: 2496

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 2496
Study: 25099924

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) administered by continuous infusion and titrated to maintain BP control
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) administered by continuous infusion
Number of subjects: 153
Study: 21745028

Group type: EXPERIMENTAL
Intervention: Combined intervention (motivational and volitional components)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Motivation first intervention
Number of subjects: 35

Group type: COMPARATOR
Intervention: Volition first intervention
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Combined intervention
Number of subjects: 35
Study: 20353588

Group type: EXPERIMENTAL
Intervention: Epoprostenol infusion for 24 hours
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo infusion for 24 hours
Number of subjects: 14
Study: 18029928

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided fine-needle aspiration biopsy
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided core needle biopsy
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Total thyroidectomy
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Chemotherapy with or without radiotherapy
Number of subjects: 6
Study: 15620484

Group type: EXPERIMENTAL
Intervention: Neuflex metacarpophalangeal joint replacement
Number of subjects: 22

Group type: COMPARATOR
Intervention: Swanson metacarpophalangeal joint replacement
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Neuflex and Swanson metacarpophalangeal joint replacements
Number of subjects: 22
Study: 11802252

Group type: EXPERIMENTAL
Intervention: CPX (8‐cyclopentyl‐1,3‐dipropylxanthine)
Number of subjects: 37
Study: 10459114

Group type: EXPERIMENTAL
Intervention: Minimal phototoxic doses (MPD)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Two thirds of the MPD
Number of subjects: 31

Group type: COMPARATOR
Intervention: One half of the MPD
Number of subjects: 31
Study: 8546293

Group type: EXPERIMENTAL
Intervention: ondansetron 0.1 mg.kg‐1
Number of subjects: 60

Group type: COMPARATOR
Intervention: droperidol 75 micrograms.kg‐1
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study: 2678331

Group type: EXPERIMENTAL
Intervention: GE-0943 6000 units
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: GE-0943 3000 units
Number of subjects: 154

Group type: COMPARATOR
Intervention: Urokinase
Number of subjects: 154
Study: 817761

Group type: EXPERIMENTAL
Intervention: Single dose intravesical thiotepa administered immediately after cystodiathermy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cystodiathermy alone (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single dose intravesical thiotepa
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continued use of adjuvant thiotepa after recurrent tumor
Number of subjects: 0
Study: 31236889

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (placebo needle puncture)
Number of subjects: 66
Study: 28802816

Group type: EXPERIMENTAL
Intervention: grazoprevir (100 mg/day) plus ruzasvir (60 mg/day) plus uprifosbuvir (450 mg/day)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: grazoprevir (100 mg/day) plus ruzasvir (60 mg/day) plus uprifosbuvir (300 mg/day)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: grazoprevir (100 mg/day) plus elbasvir (50 mg/day) plus uprifosbuvir (300 mg/day)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: grazoprevir (100 mg/day) plus elbasvir (50 mg/day) plus uprifosbuvir (450 mg/day)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Overall adverse events
Number of subjects: 241
Study: 25290658

Group type: EXPERIMENTAL
Intervention: Integrated Cognitive‐Behavioral Therapy
Number of subjects: 214

Group type: COMPARATOR
Intervention: Twelve‐Step Facilitation Therapy
Number of subjects: 214
Study: 23948313

Group type: EXPERIMENTAL
Intervention: Community-based intervention with specific factors for children and parents exposed to IPV
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control intervention based on non-specific factors
Number of subjects: 155

Group type: COMPARATOR
Intervention: Both interventions (specific factors and control)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Children in both interventions
Number of subjects: 155

Group type: COMPARATOR
Intervention: Teachers reported
Number of subjects: 155

Group type: COMPARATOR
Intervention: Higher treatment adherence in both programs
Number of subjects: 155
Study: 22200721

Group type: EXPERIMENTAL
Intervention: Shenfu Injection (SHF) pre-treatment group
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Shenfu Injection (SHF) post-treatment group
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control group (no SHF)
Number of subjects: 133
Study: 19850330

Group type: EXPERIMENTAL
Intervention: Dextroscope preoperative plans
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (no Dextroscope plans)
Number of subjects: 84
Study: 16710947

Group type: EXPERIMENTAL
Intervention: Test mask (TST) with three valves and a reservoir designed to deliver up to 80% oxygen
Number of subjects: 31

Group type: COMPARATOR
Intervention: Basic mask (BAS) without valves or oxygen reservoir bag
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Test mask (TST)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Basic mask (BAS)
Number of subjects: 31
Study: 12627928

Group type: EXPERIMENTAL
Intervention: Cefepime 2 g intravenously every 12 hours
Number of subjects: 7
Study: 10816399

Group type: EXPERIMENTAL
Intervention: Captopril renography (25 mg oral dose)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Gadolinium-enhanced MR angiography
Number of subjects: 43
Study: 8848922

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with 0.5% hyperbaric bupivacaine
Number of subjects: 433

Group type: COMPARATOR
Intervention: General anaesthesia with thiopentone, fentanyl, atracurium, nitrous oxide, and isoflurane
Number of subjects: 433

Group type: COMPARATOR
Intervention: General anaesthesia in patients aged 20-60 years
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia in men
Number of subjects: 433

Group type: COMPARATOR
Intervention: General anaesthesia in women
Number of subjects: 433
Study: 1813703

Group type: EXPERIMENTAL
Intervention: Deep level of anesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard anesthesia
Number of subjects: 0
Study: 6151528

Group type: EXPERIMENTAL
Intervention: 60 mg b.d.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 120 mg b.d.
Number of subjects: 80
Study: 30850461

Group type: EXPERIMENTAL
Intervention: In-person tutorial with a research assistant
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Link to view videos on their own
Number of subjects: 93

Group type: COMPARATOR
Intervention: Usual care comparison group
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Both training modalities (in-person and video)
Number of subjects: 93
Study: 30166846

Group type: EXPERIMENTAL
Intervention: Complete caries removal (CCR)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Partial caries removal (PCR)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 143
Study: 27270643

Group type: EXPERIMENTAL
Intervention: Type 2 Diabetes (T2DM) patients with more than 60 months duration
Number of subjects: 406

Group type: COMPARATOR
Intervention: Hypertensive patients
Number of subjects: 406

Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 406
Study: 23213050

Group type: EXPERIMENTAL
Intervention: Tier 2 small‐group tutoring in reading for 14 weeks
Number of subjects: 134
Study: 22948497

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Number of subjects: 170

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 170
Study: 20626264

Group type: EXPERIMENTAL
Intervention: LEDT treatment
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 17
Study: 17560768

Group type: EXPERIMENTAL
Intervention: Doxapram
Number of subjects: 13

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 13
Study: 16003618

Group type: EXPERIMENTAL
Intervention: Sterile gloves
Number of subjects: 269

Group type: COMPARATOR
Intervention: Clean nonsterile gloves
Number of subjects: 269
Study: 11938608

Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 6

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 6
Study: 9566827

Group type: EXPERIMENTAL
Intervention: Euglycemic hyperinsulinemic clamping (HI; plasma insulin at 150 mU/l, glucose at 4‐5 mmol/l)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hyperglycemic hyperinsulinemic clamping (HG; plasma glucose at 15 mmol/l)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 9
Study: 7995828

Group type: EXPERIMENTAL
Intervention: Triiodothyronine (0.15 microgram/kg bolus infusion after aortic cross-clamp removal; 0.1 microgram/kg before end of CPB; 0.1 microgram/kg at 4, 9, and 14 hours after CPB)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 30
Study: 2484510

Group type: EXPERIMENTAL
Intervention: Selenite, 200 micrograms daily
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Selenate, 200 micrograms daily
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: L-selenomethionine, 200 micrograms daily
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: High selenium yeast, 200 micrograms daily
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Inorganic selenium compounds (selenite, selenate)
Number of subjects: 139
Study: 31888682

Group type: EXPERIMENTAL
Intervention: Short cast (below-elbow)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Long cast (above-elbow)
Number of subjects: 74
Study: 28329131

Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg/day, once daily)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 26518597

Group type: EXPERIMENTAL
Intervention: Telephone psycho-education by a midwife
Number of subjects: 339

Group type: COMPARATOR
Intervention: Usual maternity care
Number of subjects: 339
Study: 22539817

Group type: EXPERIMENTAL
Intervention: Simvastatin/Ezetimibe 10/10 mg
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 153
Study: 22548691

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care provided by specially trained pharmacists
Number of subjects: 714

Group type: COMPARATOR
Intervention: Usual care (routine dispensing counseling)
Number of subjects: 714
Study: 19301727

Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 17717224

Group type: EXPERIMENTAL
Intervention: Partial neuromuscular block (50% depression of the first twitch)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Profound neuromuscular block (95% depression of the first twitch)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Neostigmine reversal after profound NMB
Number of subjects: 20

Group type: COMPARATOR
Intervention: Baseline measurement (control)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Noxious tetanic electrical stimulation
Number of subjects: 20
Study: 15031786

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (tenofovir DF)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Lamivudine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Lamivudine and tenofovir DF
Number of subjects: 16
Study: 16201191

Group type: EXPERIMENTAL
Intervention: Short-term antimicrobial prophylaxis (24 hours)
Number of subjects: 731

Group type: COMPARATOR
Intervention: Long-term antimicrobial prophylaxis (72 hours)
Number of subjects: 731
Study: 9443517

Group type: EXPERIMENTAL
Intervention: High oral dose of D-amphetamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low oral dose of D-amphetamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no amphetamine)
Number of subjects: 0
Study: 7944039

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 175
Study: 2465437

Group type: EXPERIMENTAL
Intervention: Ketanserin (40 mg every 12 h)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2196193

Group type: EXPERIMENTAL
Intervention: Glipizide 15 mg daily
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Glipizide
Number of subjects: 9
Study: 4569248

Group type: EXPERIMENTAL
Intervention: Cannabis (4% Delta(1)-tetrahydrocannabinol) administered orally in doses of 8, 12, and 16 milligrams
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcohol (70 grams) administered orally
Number of subjects: 0
Study: 31606826

Group type: EXPERIMENTAL
Intervention: Screening using FRAX®
Number of subjects: 12483

Group type: COMPARATOR
Intervention: Usual NHS care (Control)
Number of subjects: 12483
Study: 29059359

Group type: EXPERIMENTAL
Intervention: Arsenic as the toxic constituent, presence of an evocative image, FDA as the source
Number of subjects: 1669

Group type: EXPERIMENTAL
Intervention: Lead as the toxic constituent, presence of an evocative image, FDA as the source
Number of subjects: 1669

Group type: EXPERIMENTAL
Intervention: Arsenic as the toxic constituent, absence of an evocative image, FDA as the source
Number of subjects: 1669

Group type: EXPERIMENTAL
Intervention: Lead as the toxic constituent, absence of an evocative image, FDA as the source
Number of subjects: 1669

Group type: EXPERIMENTAL
Intervention: Arsenic as the toxic constituent, presence of an evocative image, no source
Number of subjects: 1669

Group type: EXPERIMENTAL
Intervention: Lead as the toxic constituent, presence of an evocative image, no source
Number of subjects: 1669

Group type: EXPERIMENTAL
Intervention: Arsenic as the toxic constituent, absence of an evocative image, no source
Number of subjects: 1669

Group type: EXPERIMENTAL
Intervention: Lead as the toxic constituent, absence of an evocative image, no source
Number of subjects: 1669
Study: 28330908

Group type: EXPERIMENTAL
Intervention: Dairy intervention (3 servings/d equivalent to ∼900 mg Ca/d)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control (usual intake, achieving 1000 mg Ca/d)
Number of subjects: 240
Study: 25908673

Group type: EXPERIMENTAL
Intervention: Outpatient set-up with an automated NIV device
Number of subjects: 82

Group type: COMPARATOR
Intervention: Usual inpatient set-up with nurse-led initiation of NIV
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 82
Study: 24151281

Group type: EXPERIMENTAL
Intervention: Above-knee plaster of Paris casting
Number of subjects: 26

Group type: COMPARATOR
Intervention: Below-knee plaster of Paris casting
Number of subjects: 26
Study: 21435608

Group type: EXPERIMENTAL
Intervention: JOSTENT polytetrafluoroethylene (PTFE) stent-graft
Number of subjects: 243

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 243
Study: 19711453

Group type: EXPERIMENTAL
Intervention: CD34+ cells (105/kg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: CD34+ cells (5 × 105/kg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: CD34+ cells (106/kg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 17
Study: 17526170

Group type: EXPERIMENTAL
Intervention: Modified Xiaoyao Decoction (MXD) combining clomipramine 25‐50 mg/d
Number of subjects: 105

Group type: COMPARATOR
Intervention: Clomipramine 75‐225 mg/d alone
Number of subjects: 105
Study: 15316501

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0
Study: 11981102

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous dose-adjusted UFH
Number of subjects: 0
Study: 9766458

Group type: EXPERIMENTAL
Intervention: Position change to left lateral position
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Position change to right lateral position
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Position change to supine position
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: VO2
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: DO2
Number of subjects: 42
Study: 7882602

Group type: EXPERIMENTAL
Intervention: cilazapril 2.5 mg/day
Number of subjects: 17

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17